世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

脂質ナノ粒子製造市場：脂質ナノ粒子の種類（固体脂質ナノ粒子、ナノ構造脂質キャリア）、送達分子の種類（核酸、低分子、タンパク質/ペプチド、その他）、企業規模（超大型・大型、中型・小型）別に分布、標的治療領域（感染症、腫瘍性疾患、血液疾患、希少疾患、その他の疾患）、エンドユーザーのタイプ（製薬・バイオテクノロジー企業、学術・研究機関、その他のエンドユーザー）、主要地域（北米、欧州、アジア太平洋地域、その他の地域）：業界動向と世界予測


Lipid Nanoparticle Manufacturing Market: Services and Technologies, 2023-2035 - Distribution by Type of Lipid Nanoparticle (Solid Lipid Nanoparticles and Nanostructured Lipid Carriers), Type of Molecule Delivered (Nucleic Acids, Small Molecules, Proteins/Peptides and Others), Company Size (Very Large and Large, Mid-sized and Small), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Blood Disorders, Rare Diseases and Other Disorders), Type of End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Other End-users) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts

世界の脂質ナノ粒子製造市場は、2023年には6億6,000万米ドルに達し、2023年から2035年の予測期間中に11.8%のCAGRで成長すると予測されている。 近年、製薬業界は大幅な成長を遂げており、承認プロセスや前臨床... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Roots Analysis
ルーツアナリシス 		2023年10月29日 US$4,799
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		290 英語

　

サマリー

世界の脂質ナノ粒子製造市場は、2023年には6億6,000万米ドルに達し、2023年から2035年の予測期間中に11.8%のCAGRで成長すると予測されている。

近年、製薬業界は大幅な成長を遂げており、承認プロセスや前臨床試験、臨床試験中の薬剤の数が増加しています。しかし、医薬品開発における根強い課題は、多くの化合物の水溶性と生物学的利用能の低さである。開発中の医薬品の約90％、既存の薬理学的製剤の約40％が、溶解性や浸透性に関する問題に直面している。これらの問題は、有効な吸収がなされる前に体外に排出され、効能に影響を及ぼすことが多い。その結果、製薬会社はこれらの障害を克服するための解決策を積極的に模索している。治療薬の溶解性とバイオアベイラビリティを改善する様々な戦略の中で、脂質ナノ粒子（LNP）と同様の脂質ベースの添加剤は、医薬品開発者から大きな注目を集めている。LNPは、多様な分子をカプセル化し、薬物放出を制御できることから、ナノメディシン・デリバリーにおける汎用性の高いプラットフォームと考えられている。この分野の進歩とともに、薬物送達におけるLNPの使用に関する知識ベースも拡大している。

しかし、脂質ナノ粒子の製造は複雑でコストのかかるプロセスであり、多様な専門知識を必要とする。そのため、製薬会社は、技術上および運用上の課題に対処するために必要な技術と専門知識を備えた専門の製造受託機関（CMO）を利用するようになってきている。このようなサービス・プロバイダーにアウトソーシングすることで、スポンサーは革新的なLNP技術を活用し、運用の柔軟性を得ることができる。小型、多機能特性、カスタマイズ可能な表面といった固有の利点を持つLNPベースの治療薬市場は、近い将来大きく成長すると予想される。この成長は、結果として予測期間中の脂質ナノ粒子製造市場の拡大につながるでしょう。

レポート対象範囲
 本レポートでは、脂質ナノ粒子製造市場を包括的に調査し、脂質ナノ粒子のタイプ、送達される分子のタイプ、企業規模、標的治療領域、エンドユーザーのタイプ、主要地域別に分類しています。
 市場成長要因（促進要因、阻害要因、機会、課題など）を分析し、利害関係者が直面する潜在的な利点と障害を評価します。また、市場上位企業間の競争状況についても掘り下げています。
 主要4地域に関する市場セグメントの収益予測を提供しています。本調査では、調査結果の正確性と信頼性を確保するため、前提条件、方法論、品質管理対策を含む包括的な方法論を採用しています。
 脂質ナノ粒子製造市場を形成する影響力のある要因として、過去のトレンド、為替変動、為替影響、景気後退、インフレ測定が考慮されている。
 中長期的な脂質ナノ粒子製造市場の現状と潜在的な進化を捉え、ハイレベルな概観を提示しています。
 本レポートでは、脂質、その種類、利点、医薬品への応用、製剤上の課題、製造業務のアウトソーシングの必要性の高まりについて探求している。
 評価基準には、設立年、企業規模、本社所在地、製造施設所在地、事業規模、納入分子タイプ、治療領域、提供する追加サービスなどが含まれる。
 評価項目には、製剤方法、分子タイプ、適合剤形、投与経路、治療領域、設立年、企業規模、本社所在地、ビジネスモデル、 活発な市場プレーヤーなどが含まれる。
 審査基準には、設立年、企業規模、本社所在地、製造施設、事業規模、脂質の種類、製品タイプ、提供される付加サービス、競争力分析が含まれる。
 脂質ナノ粒子受託製造組織の比較分析は、企業力、サービス品質、製造施設数に基づいて行われる。
 開発者の強み、技術的側面、治療分野での適用可能性に基づく詳細な分析を提供。
 LNP製造サービスおよび技術における主要企業の詳細なプロフィールが示されており、企業概要、ポートフォリオ、最近の開発状況、将来の展望などが記載されている。
 本レポートでは、2019年以降の関係者間のパートナーシップを、様々なパラメータと関係企業の地域分布を考慮して評価している。
 mRNAワクチン・治療薬開発企業と脂質ナノ粒子メーカー間の潜在的パートナーシップについて、複数の基準を考慮して評価を行っている。
 LNP製造の外部委託または自社能力の開発について、企業の意思決定に影響を与える要因の詳細な調査が行われている。
 企業規模、事業規模、地理的分布に基づき、LNP受託製造業者の世界的な設備能力を分析。
 脂質ナノ粒子製造市場の成長に影響を与える主な推進要因、潜在的な阻害要因、新たな機会、および既存の課題を特定し分析する。

主要市場企業
 アキュイタス・セラピューティクス
 アセンジア・ファーマシューティカルズ
 Avanti Polar Lipids
 BIOVECTRA
 コーデンファーマ
 Creative Biolabs
 キュラパス
 キュリア
 エマージェント・バイオソリューションズ
 ユーロアピ
 エボニック
 フォルマックスサイエンティフィック
 フレシニウス・カビ
 富士フイルム
 インテグレーテッド・ナノセラピューティクス
 レオンナノドラッグス
 マティナス・バイオファーマ
 メルク
 パンサーナ・セラピューティクス
 プレシジョン・ナノシステムズ
 TLCバイオサイエンス

ページTOPに戻る


目次

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Lipids
5.3 Introduction to Lipid Nanoparticles
5.3.1. Types of Lipid Nanoparticles
5.3.1.1. Solid Lipid Nanoparticles
5.3.1.2. Nanostructured Lipid Carriers
5.3.2. Advantages of Lipid Nanoparticles
5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
5.3.3.1. Cancer Treatment
5.3.3.2. Gene Therapy
5.3.3.3. Vaccine Development
5.3.3.4. Medical Imaging / Diagnostics
5.3.3.5. Additional Applications
5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
5.6. Concluding Remarks
6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
6.2.1 Analysis by Year of Establishment
6.2.2 Analysis by Company Size
6.2.3 Analysis by Location of Headquarters
6.2.4 Analysis by Company Size and Location of Headquarters
6.2.5 Analysis by Location of Lipid Nanoparticle Manufacturing Facility
6.2.6 Analysis by Scale of Operation
6.2.7 Analysis by Type of Molecule Delivered
6.2.8 Analysis by Therapeutic Area
6.2.9 Analysis by Type of Additional Services Offered
7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE
7.1. Chapter Overview
7.2. Lipid Nanoparticle: Technology Landscape
7.2.1. Analysis by Type of Formulation Method
7.2.2. Analysis by Type of Molecule Delivered
7.2.3. Analysis by Compatible Dosage Form
7.2.4. Analysis by Routes of Administration
7.2.5. Analysis by Therapeutic Area
7.3. Lipid Nanoparticle Technologies: List of Technology Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Analysis by Business Model
7.3.6. Most Active Players: Analysis by Number of Technologies
8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE
8.1. Chapter Overview
8.2. Other Types of Lipids: List of Service Providers
8.2.1 Analysis by Year of Establishment
8.2.2 Analysis by Company Size
8.2.3 Analysis by Location of Headquarters
8.2.4 Analysis by Company Size and Location of Headquarters
8.2.5. Analysis by Location of Manufacturing Facility
8.2.6. Analysis by Scale of Operation
8.2.7 Analysis by Type of Lipid Manufactured
8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
8.2.9. Analysis by Type of Product
8.2.10. Analysis by Type of Additional Services Offered
8.2.11. Analysis by Type of Product and Type of Additional Services Offered
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
9.4.1. Company Competitiveness Analysis: Small Players
9.4.2. Company Competitiveness Analysis : Mid-sized Players
9.4.3. Company Competitiveness Analysis : Large and Very Large Players
10. TECHNOLOGY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
10.4.1. Technology Competitiveness Analysis: Players based in North America
10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific
11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES
11.1. Chapter Overview
11.2. Curia
11.2.1. Company Overview
11.2.2. Service Portfolio
11.2.3. Recent Developments and Future Outlook
11.3. Emergent BioSolutions
11.3.1. Company Overview
11.3.2. Service Portfolio
11.3.3. Recent Developments and Future Outlook
11.4. EUROAPI
11.4.1. Company Overview
11.4.2. Service Portfolio
11.4.3. Recent Developments and Future Outlook
11.5. Evonik
11.5.1. Company Overview
11.5.2. Service Portfolio
11.5.3. Recent Developments and Future Outlook
11.6. Ardena
11.6.1. Company Overview
11.6.2. Service Portfolio
11.7. BIOVECTRA
117.1. Company Overview
11.7.2. Service Portfolio
11.8. Precision NanoSystems
11.8.1. Company Overview
11.8.2. Service Portfolio
12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS
12.1. Chapter Overview
12.2. Ascendia Pharmaceuticals
12.2.1. Company Overview
12.2.2. Lipid Nanoparticle Technology Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. leon-nanodrugs
12.3.1. Company Overview
12.3.2. Lipid Nanoparticle Technology Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Pantherna Therapeutics
12.4.1. Company Overview
12.4.2. Lipid Nanoparticle Technology Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. TLC Biosciences
12.5.1. Company Overview
12.5.2. Lipid Nanoparticle Technology Portfolio
12.5.3. Recent Developments and Future Outlook
12.6. Acuitas Therapeutics
12.6.1. Company Overview
12.6.2. Service Portfolio
12.7. Integrated Nanotherapeutics
12.7.1. Company Overview
12.7.2. Service Portfolio
12.8. Matinas BioPharma
12.8.1. Company Overview
12.8.2. Service Portfolio
13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS
13.1. Chapter Overview
13.2. Avanti Polar Lipids
13.2.1. Company Overview
13.2.2. Service Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Corden Pharma
13.3.1. Company Overview
13.3.2. Service Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Fujifilm
13.4.1. Company Overview
13.4.2. Service Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. Merck
13.5.1. Company Overview
13.5.2. Service Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. FormuMax Scientific
13.6.1. Company Overview
12.6.2. Service Portfolio
13.7. Creative Biolabs
13.7.1. Company Overview
13.7.2. Service Portfolio
13.8. Fresenius Kabi
13.8.1. Company Overview
13.8.2. Service Portfolio
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Lipid Nanoparticles Services and Technologies: List of Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Type of Molecule
14.3.5. Analysis by Therapeutic Area
14.3.6. Analysis by Type of Partner
14.3.7. Most Active Players: Analysis by Number of Partnerships
14.3.8. Analysis by Geography
14.3.8.1. Intracontinental and Intercontinental Deals
14.3.8.2. International and Local Deals
15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Methodology
15.2. mRNA Drug Developers: Potential Strategic Partners in North America
15.3. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific
16. MAKE VERSUS BUY DECISION FRAMEWORK
16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
16.3.1. Scenario 1
16.3.2. Scenario 2
16.3.3. Scenario 3
16.3.4. Scenario 4
16.4. Concluding Remarks
17. CAPACITY ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
17.3.1. Analysis by Range of Installed Capacity
17.3.2. Analysis by Company Size
17.3.3. Analysis by Scale of Operation
17.3.4. Analysis by Location of Manufacturing Facility
17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
17.3.5. Concluding Remarks
18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion
19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations
20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2028, 2023 and 2035
20.3.1. Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.3.2. Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.7. Data Triangulation and Validation
21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
21.3.1. Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.2. Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.3. Peptides / Proteins, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.4. Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.4. Data Triangulation and Validation
22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
22.3.1. Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.2. Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.3. Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.4. Data Triangulation and Validation
23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TARGET THERAPEUTIC AREA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
23.3.1. Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.2. Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.3. Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.4. Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.5. Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.4. Data Triangulation and Validation
24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF END-USER
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
24.3.1. Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.2. Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.3. Other End-Users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.4. Data Triangulation and Validation
25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
25.3.1. North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.3. Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.4. Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation
26. CONCLUSION
27. EXECUTIVE INSIGHTS
27.1. Chapter Overview
27.2. LIPOSOMA
27.2.1. Company Snapshot
27.3. BIOVECTRA
27.3.1. Company Snapshot
27.4. OZ Biosciences
27.4.1. Company Snapshot
28. APPENDIX 1: TABULATED DATA
29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

　

ページTOPに戻る


　

Summary

The global lipid nanoparticle manufacturing market is expected to reach USD 0.66 billion in 2023 anticipated to grow at a CAGR of 11.8% during the forecast period 2023-2035.

In recent years, the pharmaceutical industry has seen substantial growth, marked by a rising number of drugs undergoing approval processes or exploration in preclinical studies and clinical trials. However, a persistent challenge in drug development remains the poor water solubility and bioavailability of many compounds. Around 90% of drugs in development and approximately 40% of existing pharmacological products face issues related to solubility or permeability. These challenges often result in premature elimination from the body before effective absorption, impacting their efficacy. As a result, pharmaceutical companies are actively seeking solutions to overcome these hurdles. Among various strategies to improve the solubility and bioavailability of therapeutic agents, lipid nanoparticles (LNPs) and similar lipid-based additives have garnered considerable attention from drug developers. LNPs are considered a versatile platform in nanomedicine delivery due to their ability to encapsulate diverse molecules and provide controlled drug release. Alongside the advancements in this field, the knowledge base regarding the use of LNPs in drug delivery has also expanded.

However, manufacturing lipid nanoparticles is a complex and costly process that requires diverse expertise. Consequently, pharmaceutical firms are increasingly turning to specialized contract manufacturing organizations (CMOs) equipped with the necessary technology and expertise to address technical and operational challenges. Outsourcing to such service providers allows sponsors to leverage innovative LNP technologies and gain operational flexibility. With inherent advantages like small size, multifunctional properties, and customizable surfaces, the market for LNP-based therapeutics is expected to grow significantly in the near future. This growth will consequently lead to an expansion in the lipid nanoparticle manufacturing market in the projected period.

Report Coverage
 The report comprehensively examines the lipid nanoparticle manufacturing market, categorizing it by type of lipid nanoparticle, type of molecule delivered, company size, target therapeutic area, type of end-user and key geographical regions
 It analyzes market growth factors (such as drivers, restraints, opportunities, and challenges) and assesses potential advantages and obstacles faced by stakeholders. The report also delves into the competitive landscape among top market players.
 Revenue forecasts for market segments are provided concerning four major regions. The study employs a comprehensive methodology encompassing assumptions, methodologies, and quality control measures to ensure accuracy and reliability of findings.
 Historical trends, currency fluctuations, foreign exchange impact, recession, and inflation measurements are considered as influential factors shaping the lipid nanoparticle manufacturing market.
 A high-level overview is presented, capturing the current state and potential evolution of the lipid nanoparticle manufacturing market in the medium to long term.
 The report explores lipids, their types, advantages, applications in pharmaceuticals, formulation challenges, and the increasing necessity for outsourcing manufacturing operations.
 Evaluation criteria include establishment year, company size, headquarters location, manufacturing facility location, operational scale, delivered molecule types, therapeutic areas, and additional services offered.
 Assessment parameters cover formulation methods, molecule types, compatible dosage forms, administration routes, therapeutic areas, establishment year, company size, headquarters location, business models, and active market players.
 Examination criteria involve establishment year, company size, headquarters location, manufacturing facilities, operational scale, lipid types, product types, additional services offered, and competitiveness analysis.
 Comparative analysis of lipid nanoparticle contract manufacturing organizations is conducted based on company strength, service quality, and the number of manufacturing facilities.
 In-depth analysis is provided based on developer strength, technological aspects, and applicability in therapeutic areas.
 Detailed profiles of key players in LNP manufacturing services and technology are presented, including company overviews, portfolios, recent developments, and future outlooks.
 The report evaluates partnerships among stakeholders since 2019, considering various parameters and regional distribution of involved companies.
 An assessment is made regarding potential partnerships between mRNA vaccine and therapeutics developers and lipid nanoparticle manufacturers, considering multiple criteria.
 Detailed exploration of factors influencing companies' decisions to outsource LNP manufacturing or develop in-house capabilities is provided.
 Analysis of global installed capacity among LNP contract manufacturers is conducted based on company size, operational scale, and geographical distribution.
 Identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges impacting lipid nanoparticle manufacturing market growth.

Key Market Companies
 Acuitas Therapeutics
 Ascendia Pharmaceuticals
 Avanti Polar Lipids
 BIOVECTRA
 CordenPharma
 Creative Biolabs
 Curapath
 Curia
 Emergent Biosolutions
 EUROAPI
 Evonik
 Formumax Scientific
 Fresinius Kabi
 Fujifilm
 Integrated Nanotherapeutics
 leon-nanodrugs
 Matinas BioPharma
 Merck
 Pantherna Therapeutics
 Precision NanoSystems
 TLC Biosciences



ページTOPに戻る


Table of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Lipids
5.3 Introduction to Lipid Nanoparticles
5.3.1. Types of Lipid Nanoparticles
5.3.1.1. Solid Lipid Nanoparticles
5.3.1.2. Nanostructured Lipid Carriers
5.3.2. Advantages of Lipid Nanoparticles
5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
5.3.3.1. Cancer Treatment
5.3.3.2. Gene Therapy
5.3.3.3. Vaccine Development
5.3.3.4. Medical Imaging / Diagnostics
5.3.3.5. Additional Applications
5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
5.6. Concluding Remarks
6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
6.2.1 Analysis by Year of Establishment
6.2.2 Analysis by Company Size
6.2.3 Analysis by Location of Headquarters
6.2.4 Analysis by Company Size and Location of Headquarters
6.2.5 Analysis by Location of Lipid Nanoparticle Manufacturing Facility
6.2.6 Analysis by Scale of Operation
6.2.7 Analysis by Type of Molecule Delivered
6.2.8 Analysis by Therapeutic Area
6.2.9 Analysis by Type of Additional Services Offered
7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE
7.1. Chapter Overview
7.2. Lipid Nanoparticle: Technology Landscape
7.2.1. Analysis by Type of Formulation Method
7.2.2. Analysis by Type of Molecule Delivered
7.2.3. Analysis by Compatible Dosage Form
7.2.4. Analysis by Routes of Administration
7.2.5. Analysis by Therapeutic Area
7.3. Lipid Nanoparticle Technologies: List of Technology Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Analysis by Business Model
7.3.6. Most Active Players: Analysis by Number of Technologies
8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE
8.1. Chapter Overview
8.2. Other Types of Lipids: List of Service Providers
8.2.1 Analysis by Year of Establishment
8.2.2 Analysis by Company Size
8.2.3 Analysis by Location of Headquarters
8.2.4 Analysis by Company Size and Location of Headquarters
8.2.5. Analysis by Location of Manufacturing Facility
8.2.6. Analysis by Scale of Operation
8.2.7 Analysis by Type of Lipid Manufactured
8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
8.2.9. Analysis by Type of Product
8.2.10. Analysis by Type of Additional Services Offered
8.2.11. Analysis by Type of Product and Type of Additional Services Offered
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
9.4.1. Company Competitiveness Analysis: Small Players
9.4.2. Company Competitiveness Analysis : Mid-sized Players
9.4.3. Company Competitiveness Analysis : Large and Very Large Players
10. TECHNOLOGY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
10.4.1. Technology Competitiveness Analysis: Players based in North America
10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific
11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES
11.1. Chapter Overview
11.2. Curia
11.2.1. Company Overview
11.2.2. Service Portfolio
11.2.3. Recent Developments and Future Outlook
11.3. Emergent BioSolutions
11.3.1. Company Overview
11.3.2. Service Portfolio
11.3.3. Recent Developments and Future Outlook
11.4. EUROAPI
11.4.1. Company Overview
11.4.2. Service Portfolio
11.4.3. Recent Developments and Future Outlook
11.5. Evonik
11.5.1. Company Overview
11.5.2. Service Portfolio
11.5.3. Recent Developments and Future Outlook
11.6. Ardena
11.6.1. Company Overview
11.6.2. Service Portfolio
11.7. BIOVECTRA
117.1. Company Overview
11.7.2. Service Portfolio
11.8. Precision NanoSystems
11.8.1. Company Overview
11.8.2. Service Portfolio
12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS
12.1. Chapter Overview
12.2. Ascendia Pharmaceuticals
12.2.1. Company Overview
12.2.2. Lipid Nanoparticle Technology Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. leon-nanodrugs
12.3.1. Company Overview
12.3.2. Lipid Nanoparticle Technology Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Pantherna Therapeutics
12.4.1. Company Overview
12.4.2. Lipid Nanoparticle Technology Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. TLC Biosciences
12.5.1. Company Overview
12.5.2. Lipid Nanoparticle Technology Portfolio
12.5.3. Recent Developments and Future Outlook
12.6. Acuitas Therapeutics
12.6.1. Company Overview
12.6.2. Service Portfolio
12.7. Integrated Nanotherapeutics
12.7.1. Company Overview
12.7.2. Service Portfolio
12.8. Matinas BioPharma
12.8.1. Company Overview
12.8.2. Service Portfolio
13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS
13.1. Chapter Overview
13.2. Avanti Polar Lipids
13.2.1. Company Overview
13.2.2. Service Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Corden Pharma
13.3.1. Company Overview
13.3.2. Service Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Fujifilm
13.4.1. Company Overview
13.4.2. Service Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. Merck
13.5.1. Company Overview
13.5.2. Service Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. FormuMax Scientific
13.6.1. Company Overview
12.6.2. Service Portfolio
13.7. Creative Biolabs
13.7.1. Company Overview
13.7.2. Service Portfolio
13.8. Fresenius Kabi
13.8.1. Company Overview
13.8.2. Service Portfolio
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Lipid Nanoparticles Services and Technologies: List of Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Type of Molecule
14.3.5. Analysis by Therapeutic Area
14.3.6. Analysis by Type of Partner
14.3.7. Most Active Players: Analysis by Number of Partnerships
14.3.8. Analysis by Geography
14.3.8.1. Intracontinental and Intercontinental Deals
14.3.8.2. International and Local Deals
15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Methodology
15.2. mRNA Drug Developers: Potential Strategic Partners in North America
15.3. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific
16. MAKE VERSUS BUY DECISION FRAMEWORK
16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
16.3.1. Scenario 1
16.3.2. Scenario 2
16.3.3. Scenario 3
16.3.4. Scenario 4
16.4. Concluding Remarks
17. CAPACITY ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
17.3.1. Analysis by Range of Installed Capacity
17.3.2. Analysis by Company Size
17.3.3. Analysis by Scale of Operation
17.3.4. Analysis by Location of Manufacturing Facility
17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
17.3.5. Concluding Remarks
18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion
19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations
20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2028, 2023 and 2035
20.3.1. Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.3.2. Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.7. Data Triangulation and Validation
21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
21.3.1. Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.2. Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.3. Peptides / Proteins, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.4. Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.4. Data Triangulation and Validation
22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
22.3.1. Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.2. Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.3. Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.4. Data Triangulation and Validation
23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TARGET THERAPEUTIC AREA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
23.3.1. Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.2. Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.3. Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.4. Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.5. Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.4. Data Triangulation and Validation
24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF END-USER
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
24.3.1. Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.2. Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.3. Other End-Users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.4. Data Triangulation and Validation
25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
25.3.1. North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.3. Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.4. Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation
26. CONCLUSION
27. EXECUTIVE INSIGHTS
27.1. Chapter Overview
27.2. LIPOSOMA
27.2.1. Company Snapshot
27.3. BIOVECTRA
27.3.1. Company Snapshot
27.4. OZ Biosciences
27.4.1. Company Snapshot
28. APPENDIX 1: TABULATED DATA
29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

Roots Analysis社の分野での最新刊レポート

  • 最新刊レポートはありません。

本レポートと同じKEY WORD（）の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Roots Analysis社はどのような調査会社ですか?


Roots Analysisは2013年設立の医薬品・医療機器が専門の調査会社です。 医薬品の製造委託や創薬のデジタル化など、最新の医薬業界の分析を行っています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/19　10:26

155.48 円

165.11 円

199.74 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.